Compugen (CGEN) Competitors

Compugen has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.13, suggesting that its share price is 113% more volatile than the broader market.

Compugen currently has a consensus price target of $5.00, suggesting a potential upside of 119.30%. Sana Biotechnology has a consensus price target of $9.50, suggesting a potential upside of 198.74%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Compugen.

Compugen has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

12.2% of Compugen shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Sana Biotechnology had 2 more articles in the media than Compugen. MarketBeat recorded 5 mentions for Sana Biotechnology and 3 mentions for Compugen. Compugen's average media sentiment score of 0.65 beat Sana Biotechnology's score of 0.46 indicating that Compugen is being referred to more favorably in the media.

Compugen has a net margin of 47.97% compared to Sana Biotechnology's net margin of 0.00%. Compugen's return on equity of 47.72% beat Sana Biotechnology's return on equity.

In the previous week, Compugen and Compugen both had 3 articles in the media. Arbutus Biopharma's average media sentiment score of 0.97 beat Compugen's score of 0.65 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Arbutus Biopharma has a net margin of 83.95% compared to Compugen's net margin of 47.97%. Arbutus Biopharma's return on equity of 129.32% beat Compugen's return on equity.

Compugen presently has a consensus target price of $5.00, suggesting a potential upside of 119.30%. Arbutus Biopharma has a consensus target price of $5.00, suggesting a potential upside of 14.16%. Given Compugen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Compugen is more favorable than Arbutus Biopharma.

Compugen has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Compugen has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

12.2% of Compugen shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Compugen. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 3 mentions for Compugen. Amphastar Pharmaceuticals' average media sentiment score of 1.09 beat Compugen's score of 0.65 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Compugen has a net margin of 47.97% compared to Amphastar Pharmaceuticals' net margin of 11.00%. Compugen's return on equity of 47.72% beat Amphastar Pharmaceuticals' return on equity.

Compugen has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

12.2% of Compugen shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Compugen currently has a consensus target price of $5.00, indicating a potential upside of 119.30%. Amphastar Pharmaceuticals has a consensus target price of $22.00, indicating a potential upside of 17.52%. Given Compugen's stronger consensus rating and higher possible upside, research analysts plainly believe Compugen is more favorable than Amphastar Pharmaceuticals.

Theravance Biopharma presently has a consensus price target of $19.40, indicating a potential upside of 15.07%. Compugen has a consensus price target of $5.00, indicating a potential upside of 119.30%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than Theravance Biopharma.

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Theravance Biopharma has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Theravance Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Compugen has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market.

In the previous week, Compugen had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 3 mentions for Compugen and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.88 beat Compugen's score of 0.65 indicating that Theravance Biopharma is being referred to more favorably in the media.

Theravance Biopharma has a net margin of 104.34% compared to Compugen's net margin of 47.97%. Compugen's return on equity of 47.72% beat Theravance Biopharma's return on equity.